Sobi and Apellis Pharmaceuticals, Inc. announced that the first patient has been dosed in the VALIANT phase III study investigating pegcetacoplan, a targeted C3 therapy, in primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) two rare and debilitating kidney diseases with similar underlying causes and no approved treatment.
Langford IC Systems has successfully launched a cleaning machine that radically improves sanitation of surgical instruments, endoscopes and implantable devices....
Sobi and Apellis Pharmaceuticals, Inc. announced that positive results from the Phase II NOBLE study investigating pegcetacoplan for the treatment of post-transplant recurrence of primary immune complex membrano-proliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G) will be presented at the American Society of Nephrology (ASN) Kidney Week Annual Meeting.
Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in: • adults 50 years of age or older; • adults 18 years of age or older at increased risk of HZ . The use of Shingrix should be in accordance with official recommendations.
ImmunoGen Inc. announced findings from two subset analyses of the Phase III confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FR alpha)-positive platinum-resistant ovarian cancer (PROC)
Genentech, announced that the FDA has approved Tecentriq (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained greater than 50% of tumor cells [TC ? 50%] or PD-L1 stained tumor-infiltrating [IC] covering greater than 10% of the tumor area [IC ? 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
AbbVie announced that the FDA has granted full approval for Elahere (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha (FR?)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies.
ImmunoGen Inc. announced detailed results from the Phase III confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRalpha)-positive platinum-resistant ovarian cancer (PROC)
ImmunoGen Inc. announced positive top-line data from the Phase III confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRalpha)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.